Evidence map›Paper›PMID 30515718›Full record

ArticleClinical pharmacokinetics2019

Correction to: Pharmacokinetic and Pharmacodynamic Modeling to Optimize the Dose of Vestronidase Alfa, an Enzyme Replacement Therapy for Treatment of Patients with Mucopolysaccharidosis Type VII: Results from Three Trials.

Yulan Qi, Kathleen McKeever, Julie Taylor, Christine Haller, Wenjie Song, Simon A Jones, Jack Shi

Abstract readPublished Erratum
In one paragraph

Article in Clinical pharmacokinetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Yulan QiUltragenyx Pharmaceutical Inc., 60 Leveroni Court, Novato, CA, 94949, USA. yulan.qi@gmail.com.
Kathleen McKeeverUltragenyx Pharmaceutical Inc., 60 Leveroni Court, Novato, CA, 94949, USA.
Julie TaylorUltragenyx Pharmaceutical Inc., 60 Leveroni Court, Novato, CA, 94949, USA.
Christine HallerUltragenyx Pharmaceutical Inc., 60 Leveroni Court, Novato, CA, 94949, USA.
Wenjie SongUltragenyx Pharmaceutical Inc., 60 Leveroni Court, Novato, CA, 94949, USA.
Simon A JonesWillink Unit, Manchester Centre for Genomic Medicine, Saint Mary's Hospital, Manchester and Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
Jack ShiUltragenyx Pharmaceutical Inc., 60 Leveroni Court, Novato, CA, 94949, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction section, para 3, lines 2-4 which previously read.

Identifiers

PMID30515718
PMCPMC6828067

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.